Purpose: Radiological characterization of pulmonary tumors may be difficult and invasive. Needle biopsy may produce false-negative results. 18 F-FDG PET/CT is an established noninvasive procedure for lung tumor characterization and staging. This study was aimed at differentiating bronchopulmonary carcinoids from hamartomas and typical from atypical bronchopulmonary carcinoids by means of 18 F-FDG PET/CT. Patients and Methods: In a retrospective analysis of 118 patients, with surgically resected pulmonary carcinoid tumors and hamartomas, 87 of those selected had also undergone 18 F-FDG PET/CT preoperatively and constituted the study population. To better assess the tracer accumulation, especially in small lesions, the 18 F-FDG uptake (SUV) in the tumors was corrected for partial volume effect by applying recovery coefficients corresponding to the respective various specific tumor volumes, as extrapolated from those obtained from experiments in a NEMA phantom. Results: The SUV max was higher in the pulmonary carcinoids (mean, 3.9) than in the hamartomas (mean, 1.4; P ≤ 0.00001) and higher in the subgroup of peripheral carcinoids than in hamartomas (P ≤ 0.00001). The SUV max was similar for the atypical and typical carcinoids, 5.0 and 3.8, respectively, because of the large variation in the data (P = 0.11). Conclusions: Using PET measurements of the 18 F-FDG uptake (SUV max ) in the tumors, corrected for partial volume effects, it was possible to differentiate the carcinoids from the hamartomas, but the clinically more aggressive atypical carcinoids could not be differentiated from the typical carcinoids.
B ronchopulmonary carcinoids comprise 20% to 30% of all neuroendocrine tumors (NETs) and 2% to 5% of all primary lung malignancies. [1] [2] [3] [4] [5] [6] Differential diagnoses include, for example, hamartomas, inflammatory pseudotumors, infectious lesions, other lung cancers, and metastases. [7] [8] [9] Hamartoma is the most frequent benign lung tumor. When peripheral carcinoids and hamartomas present as small lesions, both CT-guided biopsy and bronchoscopic biopsy may be difficult. Further diagnostic workup is therefore often needed, usually comprising PETwith 18 F-FDG combined with CT. Despite the many publications on PET/CT imaging of lung cancer, only a few studies focus on bronchopulmonary carcinoids. 3, [10] [11] [12] [13] [14] [15] [16] The tumor uptake of 18 F-FDG was shown to be a predictor of progression-free survival in a study of 98 NET patients with a subgroup of 8 patients with typical and atypical bronchopulmonary carcinoids. 17 Atypical carcinoids might be 18 F-FDG positive because of their higher mitotic count, 18 and this can be helpful to differentiate them from hamartomas, which show no or low uptake. 9 The SUV is routinely used to quantify the PET tracer uptake in tumors and other tissues. Because the SUVassumes a tissue density of 1 g/mL, this approximation will be adequate for soft tissues but not for lung and bone. Other factors influencing the SUVare PET camera based and patient related. [19] [20] [21] [22] The partial volume effect (PVE) has a major impact on the quantification of tumor uptake. This influence depends heavily on the finite spatial resolution of the PET system and the distribution of the tracer uptake in the tumor and surrounding tissues. 22 This limited spatial resolution results in an underestimation of the tracer concentration in the image. Quantitatively, this underestimation is a function of the lesion size, increasing as the lesion size decreases below the PET camera intrinsic resolution. Yet another factor is motion during PET acquisition, for example, respiratory movements. According to experimental results using phantom analyses, 20 the contribution to image blur in lung tissue was up to 3 times larger than in soft tissue or fat and 5 times larger than in bone tissue. Approaches for correcting and assessing the blurring are still under evaluation. 19, 23 The primary goal of this retrospective study was to differentiate bronchopulmonary carcinoids from hamartomas by means of 18 F-FDG PET/CT. For this purpose, the 18 F-FDG uptake (SUV) in the tumors was corrected for PVE to better assess the uptake in small lesions. The second goal was to analyze whether this approach can distinguish typical from atypical bronchopulmonary carcinoids.
PATIENTS AND METHODS

Patients
The study was approved by the regional ethics and the hospital's radiation protection committees. We performed a retrospective analysis of 87 of 118 patients with a histopathologically proven diagnosis of bronchopulmonary carcinoid tumors and hamartomas, surgically resected at the Karolinska University Hospital, Stockholm, Sweden, between October 2005 and February 2012 and who had also undergone 18 F-FDG PET/CT preoperatively. Of 118 patients, 31 who had not undergone preoperative thoracic 18 F-FDG PET/ CT were excluded from further evaluation. All patients were referred to 18 F-FDG PET/CT on the suspicion of lung cancer based on chest x-ray and in some cases equivocal findings on CT. The final diagnosis was based on the histopathological evaluation of surgical specimens. The carcinoid tumors were further subclassified as typical or atypical based on the World Health Organization's criteria. 24 Histopathological features, mitotic count, and presence or absence of necrosis were assessed as follows: tumors were defined as typical carcinoids when the mitotic count was less than 2/10 high-power fields and there was no sign of necrosis, and as atypical carcinoids when the mitotic count was more than 2/10 high-power fields or there was evidence of necrosis. As an additional measure of proliferation, the proliferation marker Ki-67 score was also determined and expressed as the percentage of positively stained cells among the total number of cells within at least 10 randomly selected high-power fields. There was not any Ki-67 labeling index data for the hamartomas.
As opposed to patients with gastroenteropancreatic NETs, those with lung carcinoids rarely express elevated biochemical tumor markers. This was also the case in the present group of patients, in whom biochemistry in this regard was normal.
Patient characteristics are listed in Table 1 . Bronchopulmonary carcinoids arising distal to segmental bronchi were radiologically considered as peripheral.
PET/CT
A Biograph 64 TruePointTrueV PET/CT scanner (Siemens Medical Solutions, Erlangen, Germany) was used. All patients fasted for at least 4 hours before the examination. Four millibecquerel/ kilogram body weight (0.1081 mCi/kg body weight) of 18 F-FDG was administered intravenously (maximum dosage, 300 MBq [8.1081 mCi]), and examination was started after 50 to 70 minutes of resting. The scanned area included the base of the skull to the proximal thighs. Before examination with contrast medium, a lowdose CT scan was performed for attenuation and photon scatter correction. Directly thereafter, the PET examination was done, followed by a diagnostic CT with contrast medium. The PET acquisition was done in 3D, 3 minutes per bed position, during normal tidal breathing. In all patients, a diagnostic (full radiation dose) CT was performed during IV contrast enhancement in the large majority of patients. Occasional examinations were performed without IV contrast enhancement. At examinations where contrast medium was not used, a full-dose diagnostic CT was performed and also used for attenuation and scatter correction. The diagnostic CT examinations were performed with a tube tension of 120 kV, a pitch of 0.8, a slice thickness of 1.2 mm, and a rotation speed of 0.5 second. The x-ray tube current was set to a reference value of 160 mA, and dose modulation (CARE Dose4D) was applied. The protocol for the CT examination done only for photon attenuation and scattering correction is similar to the diagnostic CT but with a reduced reference x-ray tube current of 50 mA. The PET data were subsequently reconstructed with the manufacturer's 2D-OSEM algorithm (4 iterations and 8 subsets) using a 5-mm postreconstruction Gaussian filter. The image matrix size was 168 Â 168 with a slice thickness of 5 mm. Data were also corrected for photon scattering, acquisition dead time, and random coincidences.
Partial Volume Correction
The PVE on the SUV calculations was assessed by using the NEMA IEC body phantom. 23 The spheres of the phantom were homogeneously filled with 18 F-FDG of equal concentration so that the PET image pixel values obtained within each sphere would have the same SUV = 1. No background activity was used. The protocol for acquisition and image reconstruction described previously was also used for the phantom experiments. Volumes of interest (VOIs) corresponding with the sphere contour were automatically created for each sphere by using the CT examination. The average SUV within each VOI was registered thereafter. PET image recovery coefficients as a function of object size were then calculated as the ratio of the measured mean SUV and the expected SUV = 1 for each sphere size.
PET Measurements
By using the commercial software supplied by the manufacturer, a VOI was allocated around the tumor activity in the transaxial PET images with a small margin and the SUV of the pixel with the highest radioactivity concentration (SUV max ) was registered. The volume of the tumor was then approximated by using the ellipsoid formula and measurements of 3 orthogonal axes in the CTexaminations using multiplanar reformatted images with a nominal thickness of 1.5 mm. Partial volume correction of the SUV max was performed by applying the recovery coefficient corresponding to the specific tumor volume as extrapolated from the values obtained from the NEMA phantom.
Statistical Analysis
The partial volume corrected PET results were grouped, according to the histopathological findings, as bronchopulmonary carcinoids and hamartomas, respectively, and the SUV max . Statistical differences between groups were tested. The statistical difference in SUV max between carcinoids and hamartomas at group level was first investigated using a t test. Thereafter, the difference in SUV max between hamartomas and peripheral carcinoids at group level was also tested for significance using a t test. Statistical differences in SUV max between central and peripheral carcinoids as well as between typical and atypical carcinoids were sought using a nonparametric Wilcoxon rank sum test. For all tests, P < 0.05 was considered statistically significant. Finally, linear correlation between the SUV max and Ki-67 was investigated for the pooled bronchopulmonary carcinoids.
The average size of the hamartomas appeared slightly smaller than the carcinoids (P = 0.000024, t test). However, size was not discriminative because some of the hamartomas were larger in size than the average size of the carcinoids.
RESULTS
In total, 36 patients with bronchopulmonary carcinoids and 51 patients with hamartomas were evaluated further in this study. Among the carcinoids, 25 were classified as typical, 6 as typical with lymph node metastasis, and 5 as atypical (3 with lymph node metastasis). Thirteen of 36 carcinoids were peripheral, of which 11 were typical, one typical with metastasis to the contralateral lung, and one was atypical. The PVE corrected SUV max was significantly higher in the carcinoids compared with that in the hamartomas (P ≤ 0.00001). Similarly, the SUV max of the subgroup of peripheral carcinoids was higher than that of the hamartomas (P ≤ 0.00001; Fig. 1 ). The average SUV max at group level was 1.4 for hamartomas and 3.9 for pooled pulmonary carcinoids. No statistically significant difference was found in SUV max at group level between centrally and peripherally located carcinoids (P = 0.8; Wilcoxon rank sum test). However, there was a trend for higher SUV max in centrally located compared with peripherally located carcinoids, showing mean SUV max of 4.0 and 3.9, respectively. The SUV max in the atypical and typical carcinoids was similar because of the large variation in the data (mean [SD], 5.0 [2.6] and 3.8 [1.9], respectively; P = 0.11; Fig. 2 ). Moreover, when testing for differences between atypical carcinoids and typical carcinoids with metastasis (average SUV max , 3.9; Fig. 2) , the results were also similar. The subgroup of typical bronchopulmonary carcinoids showed SUV max greater than 2.0, independent of the presence or absence of distant metastasis. The Ki-67 was lower in typical (with and without metastasis) carcinoids (mean [range], 2% [0%-12%) than for the atypical (with and without metastasis) carcinoids (mean [range], 10% [3%-20%]; P = 0.0054). No correlation was found between SUV max for pooled carcinoids and Ki-67 score, linear coefficient of determination R 2 = 0.003. As a cutoff for malignancy, a SUV max of 1.5 was applied, similar to the average SUV max for the hamartomas. The resulting sensitivity, specificity, positive predictive value, and negative predictive value (NPV) for 18 F-FDG PET/ CT to differentiate bronchopulmonary carcinoids from hamartomas were 92%, 69%, 67%, and 92%, respectively ( Table 2) .
DISCUSSION
This study includes 36 verified bronchopulmonary carcinoids and 51 hamartomas. To the best of our knowledge, this is the largest number of tumors in a study of the value of 18 F-FDG PET/CT.
Carcinoids Versus Hamartomas
Because the diagnosis was not achieved preoperatively, it became postoperatively apparent that the surgical resection had been unnecessary in 51 patients with benign lung lesions. Because of the wide availability and the increasing use of high spatial resolution multidetector CT, and in combination with the implementation of lung cancer screening programs, a substantial number of lung lesions are detected, 25 which need to be characterized. The Fleischner Society has suggested a program for CT follow-up and management of small pulmonary nodules. 26 The most commonly used diagnostic procedures are bronchoscopy and transthoracic needle aspiration, with the risk of pneumothorax and false-negative results. The present results show that there was significantly higher 18 F-FDG uptake in bronchopulmonary carcinoids than in hamartomas. Notably, although in selected material, with an NPV of 92%, the risk of missing a pulmonary carcinoid was very low. Recent 18 F-FDG PET/CT studies support our results, showing that lung carcinoids can be 18 F-FDG avid to indicate malignancy. 12, 13, 15, 18 
Typical Versus Atypical Carcinoids
The typical carcinoid is considered a low-grade neoplasm, whereas the atypical carcinoid is of intermediate grade. This is reflected in the 40% to 69% 5-year survival rate for patients with atypical carcinoids compared with 87% to 100% for patients with typical carcinoids. 27 Data from a recently published study, including 29 pulmonary carcinoids (23 typical and 6 atypical), showed that the mean SUV max in the atypical carcinoids was significantly higher than in the typical ones, 8.1 and 2.7, respectively. 28 The SUV max did not differentiate the 26 typical from the 5 atypical carcinoids in our own study, presented here. 
Central Versus Peripheral Carcinoids
Peripherally located carcinoids are often a diagnostic challenge, presenting difficulties for cytological and histopathological verification by CT-guided percutaneous needle biopsy. The 14 peripherally located carcinoids in our study were clearly distinguished from lesions of benign origin as based on their mean SUV max . 18 
F-FDG Uptake and Lesion Size
The tumor sizes in our study varied between 7 and 53 mm. The smallest of these was similar to the intrinsic spatial resolution of the PET system we used (6-mm full width at half maximum in the center of the field of view). It is well known that semiquantitative measurement of SUV in tumors is highly dependent on lesion size 29 and that the PVE has a major effect on this measurement. Lesions below or close to the intrinsic spatial resolution of the PET camera might be detected but show an apparent 18 F-FDG uptake much lower than the true radioactivity concentration. The accuracy of the PVE correction used in this work is limited because the basic assumptions that the tumor is spherical and that the activity within the tumor is homogeneously distributed may not always be met. Despite this, there is no reason to believe that the applied PVE correction would introduce a systematic error into our findings.
SUV max Cutoff
For purely visual assessment of pulmonary tumors, an 18 F-FDG uptake in the tumor higher than that of the normal mediastinal blood pool is often used as an indication of malignancy. 29 The choice of cutoff for 18 F-FDG positive uptake clearly influences the outcome of the confusion matrix described in Table 2 . In this clinical study, 2 factors were considered more relevant to establish such a cutoff: the median SUV max for all hamartomas (SUV max , 1.4) and the NPV of 18 F-FDG PET. A cutoff for SUV max of 1.5 for positive 18 F-FDG uptake maximized the NPV (92%) in our data. The present study comprises a large number of patients, exceeding what has previously been published, and allows for better statistical power. We have also corrected the SUV measurements for the PVE to enable a more precise quantification of the 18 F-FDG uptake and consequently to allow for more accurate comparisons between tumor groups. An inherent limitation of the retrospective design of this study is that the acquired PET data are based on an examination protocol without breathing gating.
The relatively low positive predictive value of 67% indicated a fairly high rate of false-positive results in our study. Hence, 
